What is Ganoderma lucidum or Reishi?
Ganoderma lucidum (Reishi), also known as immortality mushroom, is one of the most famous and appreciated medicinal mushrooms because of its broad arsenal of medicinal properties. It has been used for centuries in traditional Chinese medicine to promote “health and longevity” and is still considered a superior remedy.
Ganoderma lucidum contains numerous biologically active substances such as polysaccharides, terpenes, steroids and nucleosides that give the mushroom such a wide range of therapeutic properties. Scientific studies have shown that the polysaccharides of Ganoderma lucidum regulate the immune system, mainly through improved cellular immunity. The antitumoral activity of these polysaccharides, including beta(ß)-glucans, has been demonstrated in clinical trials on cancer patients, in addition to conventional treatment. The quality of life of these patients also improved.
The triterpenes such as Ganoderic acid A & B in reishi contain cell-regulating, antioxidant and anti-inflammatory properties so that they also have a positive effect in numerous degenerative diseases.
Ganoderma lucidum also helps prevent cardiovascular disease and has a beneficial effect on diabetes, respiratory and gastrointestinal disorders, liver and kidneys. It also exhibits antiviral and antibacterial activity. In addition, no significant adverse side effects or toxicity have been observed with reishi which makes it a safe ingredient.
Why choosing Ganoderma lucidum (Reishi) through submerged fermentation?
Submerged cultivation is the best technology to manage the identity and purity of medicinal mushrooms without contamination. The bioactive substances of mushrooms are identified not only in the fruit body, but also in the mycelium culture and broth.
The most powerful ß -glucans are found in the mycelium, because the defence of the mushroom is most needed in the substrate. They are the so-called branched ß- 1,3-1,6 glucans.
After long and complex research, it has been possible to make liquid substrates for the different mushrooms where the mycelium can develop under ideal conditions. A sterile and liquid substrate is used where the mycelium is introduced and further develops for several weeks. When the mycelium is fully developed, everything is filtered. The filtration removes the not converted liquid substrate, but also the less active ß -glucans. Low-temperature membrane filtration with a molecular weight cut-off (MWCO) of 5,000 Da produces high-molecular ß-glucans that are highly bioactive. The filtrate containing the excreted beta-glucans, but also the mycelium is then freeze-dried.
This (expensive) technique guarantees optimal preservation of the triple helix structure of the ß -glucans, i.e. a biological activity that is not affected. The triple helix structure in most mushroom powders is largely damaged by heating and extraction using solvents.
Triple helix structure
Because we use a sterile substrate that allows the mycelium to develop in a sterile environment, the final product is also not bacterially contaminated. So extremely safe!
The use of submerged fermentation also ensures that a relatively high amount of Ganoderic A & B is formed, and this is unique!
Ganoderma lucidum mycelium GL12 shows a clear genetic similarity to fruiting bodies that grow naturally.
Fermedics’ mushroom powders belong to the top of the world due to the advanced & unique production process in which a high concentration of active substances with an enormous stability and high efficiency is achieved.
Unique properties of the production process
- Produced by patented submerged fermentation
- Subjected to low temperature membrane filtration technology
- Reliable strain identification by DNA Sequence alignment (ITS1, 5.8 DNA, ITS2)
- Very similar to wild type (WT) strain
- Assessment of long-term storage
- Active ingredient analyses and full safety assessment
- High content of secondary metabolites and bioactive compounds
- Bio-sustainability & environmentally friendly
- Free of contaminants such as pesticides and heavy metals
What makes Ganoderma lucidum mycelium GL12 so special?
- Contains the most effective beta-glucans because of the:
- preservation of the triple helix structure
- very high absorbability due to water solubility
- presence of high molecular weight extracellular beta-glucans
- Specific branching (β-1,3 – β-1,6 glucans) which are more biologically active
- Strong similarity to the wild variety through reliable strain identification
- 100% pure polysaccharides and beta-glucans derived from the mycelium and extracellular excretion in the fermentation fluid
- No risk of contamination (microbiological as well as chemical)
- Relatively high amount of Ganoderic acid A & B due to submerged fermentation
- 100 % pure powder
- no heavy metal contamination
- no pesticides/fungicides
- no chemical additives
- no extraction with solvents destroying triple helix structure
- No functional starch derivatives, cyclodextrin, modified starches or other thickeners as additives
- No traces of starch or cereals from the culture matrix or substrate.
- No subsequent addition of polysaccharides.
- Antioxidative and anti-inflammatory properties
- Blood sugar regulation
- Cardiovascular protection
- Immune support
- Liver and kidney support
Ganoderma lucidum is authorized in EU for use in food supplements.
Ganoderma lucidum is permitted in Belgium. This mushroom is listed in The Royal Decree of 29 August 1997 on the manufacture and trade of foodstuffs composed or containing plants or plant preparations.
Ganoderma lucidum is on the Belfrit list and is allowed in Belgium, France and Italy.
Fermedics offers you on request all technical data of this ingredient, such as Certificate of Analysis (COA), and price quotation.
Due to the hygroscopic nature, please store at dry conditions in an airtight container. Shelf life is at least two years at 25°C and below 70% RH in original sealed package.
MOQ (minimum order quantity) 20 kg
|Powder||Nutritional supplements Functional food||0,5 – 1,0 g/day||Polysaccharides > 12 % |
β-glucans > 12 %
Ganoderic acid A > 50 μg/g
Ganoderic acid B > 50 μg/g
- Chen S.D., Hsieh M.C., Chiou M.T., Lai Y.S., Cheng Y.H. 2008b. Effects of fermentation products of Ganoderma lucidum on growth performance and immunocompetence in weanling pigs. Archives of Animal Nutrition, 62, 1: 22–32.
- Gao Y., Chen G., Dai X., Ye J., Zhou S. 2004a. A phase I/II study of ling zhi mushroom Ganoderma lucidum extract in patients with coronary heart disease. International Journal of Medicinal Mushrooms, 6, 4: 327-334.
- Gao Y., Lan J., Dai X., Ye J., Zhou S. 2004b. A phase I/II study of ling zhi mushroom Ganoderma lucidum extract in patients with type II diabetes mellitus. International Journal of Medicinal Mushrooms, 6, 1: 33–40.
- Jin X., Ruiz Beguerie J., Sze D.M.Y., Chan G.C.F. 2012. Ganoderma lucidum (Reishi mushroom) for cancer treatment. The Cochrane Database of Systematic Reviews, 6, doi: 10.1002/14651858. CD007731.pub2.
- Li, A., Shuai, X., Jia, Z., Li, H., Liang, X., Su, D., and Guo, W. (2015). Ganoderma lucidum polysaccharide extract inhibits hepatocellular carcinoma growth by downregulating regulatory T cells accumulation and function by inducing microRNA-125b. Journal of translational medicine 13, 100.
- Li, K., Yu, M., Hu, Y., Ren, G., Zang, T., Xu, X., and Qu, J. (2016). Three kinds of Ganoderma lucidum polysaccharides attenuate DDC-induced chronic pancreatitis in mice. Chemico-biological interactions 247, 30-38.
- Liang, Z., Yi, Y., Guo, Y., Wang, R., Hu, Q., and Xiong, X. (2014). Chemical characterization and antitumor activities of polysaccharide extracted from Ganoderma lucidum. International journal of molecular sciences 15, 9103-9116.
- Lin Z.B. 2005. Cellular and molecular mechanisms of immuno-modulation by Ganoderma lucidum. Journal of Pharmacological Sciences, 99, 2: 144–153.
- Radwan, F.F., Hossain, A., God, J.M., Leaphart, N., Elvington, M., Nagarkatti, M., Tomlinson, S., and Haque, A. (2015). Reduction of myeloid-derived suppressor cells and lymphoma growth by a natural triterpenoid. Journal of cellular biochemistry 116, 102-114.
- Sone, Y., Okuda, R., Wada, N., Kishida, E., and Misaki, A. (1985). Structures and anti-tumor activities of the polysaccharides isolated from fruiting body and the growing culture of mycelium of Ganoderma lucidum. Agricultural and Biological Chemistry 49, 2641-2653.
- Wachtel-Galor S., Yuen J., Buswell J.A., Benzie I.F.F. 2011. Ganoderma lucidum (lingzhi or reishi) a medicinal mushroom. In: Herbal medicine: Biomolecular and clinical aspects. 2nd edition. Benzie I.F.F., Wachtel-Galor S. (editors). Boca Raton, FL, CRC Press: 175–199.
- Zhang, G.-L., Wang, Y.-H., Ni, W., Teng, H.-L., and Lin, Z.-B. (2002). Hepatoprotective role of Ganoderma lucidum polysaccharide against BCG-induced immune liver injury in mice. World journal of gastroenterology 8, 728.